EVOTEC SE ADR 1/2 O.N. (F:EVTA) — Market Cap & Net Worth
Market Cap & Net Worth: EVOTEC SE ADR 1/2 O.N. (EVTA)
EVOTEC SE ADR 1/2 O.N. (F:EVTA) has a market capitalization of $792.54 Million (€677.91 Million) as of June 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #10143 globally and #1212 in its home market, demonstrating a 3.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EVOTEC SE ADR 1/2 O.N.'s stock price €2.66 by its total outstanding shares 355188058 (355.19 Million). Review EVTA current and long-term liabilities to assess the company's total debt and financial obligations.
EVOTEC SE ADR 1/2 O.N. Market Cap History: 2015 to 2026
EVOTEC SE ADR 1/2 O.N.'s market capitalization history from 2015 to 2026. Data shows growth from $851.68 Million to $896.94 Million (2.93% CAGR).
EVOTEC SE ADR 1/2 O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EVOTEC SE ADR 1/2 O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.39x
EVOTEC SE ADR 1/2 O.N.'s market cap is 1.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $8.55 Billion | $618.03 Million | $215.51 Million | 13.84x | 39.69x |
| 2022 | $3.20 Billion | $751.45 Million | -$175.66 Million | 4.26x | N/A |
| 2023 | $4.36 Billion | $781.43 Million | -$83.91 Million | 5.58x | N/A |
| 2024 | $1.71 Billion | $796.97 Million | -$196.08 Million | 2.15x | N/A |
| 2025 | $1.10 Billion | $788.37 Million | -$103.52 Million | 1.39x | N/A |
Competitor Companies of EVTA by Market Capitalization
Companies near EVOTEC SE ADR 1/2 O.N. in the global market cap rankings as of June 18, 2026.
Key companies related to EVOTEC SE ADR 1/2 O.N. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
EVOTEC SE ADR 1/2 O.N. Historical Marketcap From 2015 to 2026
Between 2015 and today, EVOTEC SE ADR 1/2 O.N.'s market cap moved from $851.68 Million to $ 896.94 Million, with a yearly change of 2.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €896.94 Million | -18.18% |
| 2025 | €1.10 Billion | -35.92% |
| 2024 | €1.71 Billion | -60.76% |
| 2023 | €4.36 Billion | +36.36% |
| 2022 | €3.20 Billion | -62.62% |
| 2021 | €8.55 Billion | +40.85% |
| 2020 | €6.07 Billion | +28.29% |
| 2019 | €4.73 Billion | +38.18% |
| 2018 | €3.43 Billion | +21.89% |
| 2017 | €2.81 Billion | +87.72% |
| 2016 | €1.50 Billion | +75.79% |
| 2015 | €851.68 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of EVOTEC SE ADR 1/2 O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $792.54 Million USD |
| MoneyControl | $792.54 Million USD |
| MarketWatch | $792.54 Million USD |
| marketcap.company | $792.54 Million USD |
| Reuters | $792.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more